We are live on
!
Find out more
Adage Capital Partners Portfolio holdings
AUM
$71.3B
1-Year Est. Return
56.8%
This Fund
S&P 500
This Quarter
Est. Return
+1.53%
1 Year Est. Return
+56.8%
3 Year Est. Return
+170.28%
5 Year Est. Return
+249.16%
10 Year Est. Return
+1,067.32%
AUM
$64.8B
AUM Growth
-$1.23B
(-1.9%)
Cap. Flow
+$395M
Cap. Flow
% of AUM
0.61%
Top 10 Holdings %
Top 10 Hldgs %
28.4%
Holding
1,116
New
212
Increased
277
Reduced
389
Closed
160
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Revolution Medicines
RVMD
|
+$330M |
| 2 |
CTRA
Coterra Energy
CTRA
|
+$214M |
| 3 |
Boston Scientific
BSX
|
+$204M |
| 4 |
RB Global
RBA
|
+$183M |
| 5 |
Chevron
CVX
|
+$131M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RNAM
Avidity Biosciences
RNAM
|
+$190M |
| 2 |
Royalty Pharma
RPRX
|
+$187M |
| 3 |
Dover
DOV
|
+$178M |
| 4 |
Boeing
BA
|
+$168M |
| 5 |
Devon Energy
DVN
|
+$155M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.24% |
| 2 | Healthcare | 15.45% |
| 3 | Financials | 12.46% |
| 4 | Industrials | 9.23% |
| 5 | Communication Services | 8.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1051
Procept Biorobotics
PRCT
$1.24B
| – | – |
-389,278
| Closed | -$12.2M |
|
1052
Privia Health
PRVA
$2.81B
| – | – |
-74,346
| Closed | -$1.76M |
|
1053
PTC Therapeutics
PTCT
$5.98B
| – | – |
-141,000
| Closed | -$10.7M |
|
1054
Quince Therapeutics
QNCX
$34.7M
| – | – |
-11,250
| Closed | -$7.54M |
|
|
RAPT
1055
DELISTED
RAPT Therapeutics
RAPT
| – | – |
-275,000
| Closed | -$9.31M |
|
1056
RadNet
RDNT
$6.02B
| – | – |
-476,626
| Closed | -$34M |
|
|
RNAM
1057
DELISTED
Avidity Biosciences
RNAM
| – | – |
-2,630,966
| Closed | -$190M |
|
1058
ReNew
RNW
$2.48B
| – | – |
-250,000
| Closed | -$1.41M |
|
1059
Ryan Specialty Holdings
RYAN
$10.7B
| – | – |
-1,610,000
| Closed | -$83.1M |
|
1060
SI-BONE Inc
SIBN
$848M
| – | – |
-75,000
| Closed | -$1.48M |
|
1061
Selective Insurance
SIGI
$5.62B
| – | – |
-280,000
| Closed | -$23.4M |
|
1062
Skyward Specialty Insurance
SKWD
$2.44B
| – | – |
-248,708
| Closed | -$12.7M |
|
1063
SL Green Realty
SLG
$3.99B
| – | – |
-280,000
| Closed | -$12.8M |
|
1064
SharkNinja
SN
$26B
| – | – |
-70,000
| Closed | -$7.83M |
|
1065
Schneider National
SNDR
$6.33B
| – | – |
-102,516
| Closed | -$2.72M |
|
1066
Shutterstock
SSTK
$208M
| – | – |
-197,030
| Closed | -$3.76M |
|
1067
STAAR Surgical
STAA
$1.28B
| – | – |
-159,765
| Closed | -$3.69M |
|
1068
Stellantis
STLA
$20.1B
| – | – |
-1,750,000
| Closed | -$19.1M |
|
1069
Synchrony
SYF
$26.2B
| – | – |
-78,361
| Closed | -$6.54M |
|
1070
Stryker
SYK
$130B
| – | – |
-109,720
| Closed | -$38.6M |
|
1071
Protara Therapeutics
TARA
$230M
| – | – |
-1,043,478
| Closed | -$5.56M |
|
1072
Terex
TEX
$7.76B
| – | – |
-215,000
| Closed | -$11.5M |
|
|
TGNA
1073
DELISTED
TEGNA Inc
TGNA
| – | – |
-667,172
| Closed | -$12.9M |
|
1074
Tandem Diabetes Care
TNDM
$1.56B
| – | – |
-182,995
| Closed | -$4.02M |
|
1075
Taysha Gene Therapies
TSHA
$1.86B
| – | – |
-1,328,000
| Closed | -$7.3M |
|
Similar funds
BC
Adage Capital Partners's Q1 2026 Portfolio in Review
As of Q1 2026, Adage Capital Partners held 1,116 positions worth $64.8B, down 1.9% from $66.1B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Adage Capital Partners's Q1 2026 filing shows 212 new, 277 increased, 389 reduced and 160 closed positions. Its largest new stake was Takeda Pharmaceutical: 6,424,984 shares worth $119M. The largest sale was Avidity Biosciences, an estimated $190M.
By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 29% a quarter earlier, followed by Healthcare and Financials.
- Adage Capital Partners's largest Q1 2026 buy was Takeda Pharmaceutical: 6,424,984 shares worth $119M.
- Adage Capital Partners added most to Revolution Medicines in Q1 2026, an estimated $330M increase.
- Adage Capital Partners's biggest Q1 2026 reduction was Royalty Pharma, cutting an estimated $187M.
- Adage Capital Partners fully exited Avidity Biosciences in Q1 2026, selling an estimated $190M.
- Adage Capital Partners's ten largest holdings make up 28% of its $64.8B portfolio in Q1 2026.
- Adage Capital Partners opened 212 new positions and closed 160 in Q1 2026.
- Adage Capital Partners's portfolio value fell 1.9% quarter-over-quarter to $64.8B.
Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.